SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden	
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*
Sanofi

(Last) (First) (Middle)
46 AVENUE DE LA GRANDE ARMEE

(Street)
PARIS 75017

(City) (State) (Zip)
FRANCE

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name **and** Ticker or Trading Symbol
Latigo Biotherapeutics, Inc. [LTGO]
Foreign Trading Symbol

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
☑ 10% Owner
Officer (give title below)
Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)
☑ Form filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(1)	Common Stock	494,800	(1)	I(3)	See footnote(3)
Convertible Promissory Note	(2)	(2)	Common Stock	177,978	(2)	I(3)	See footnote(3)

Explanation of Responses:

1. Series B Preferred Stock (the "Preferred Stock") is convertible into shares of common stock on a one-for-one basis at the option of the holder, and converts automatically upon closing of the Issuer's initial public offering (the "IPO") without payment of consideration. The Preferred Stock has no expiration date.
2. The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converts into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. The Note otherwise matures on June 17, 2027.
3. Sanofi is the beneficial owner of the securities through various wholly-owned subsidiaries.

/s/ Alexandra Roger, as attorney-in-fact for Sanofi — 08/12/2026

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.